US2014154300A1PendingUtilityA1

Methods and compositions for treatment of lesioned sites of body vessels

67
Assignee: ABBOTT CARDIOVASCULAR SYSTEMSPriority: Apr 14, 2006Filed: Feb 7, 2014Published: Jun 5, 2014
Est. expiryApr 14, 2026(expired)· nominal 20-yr term from priority
Inventors:Florian N. LudwigStephen D. PacettiPaul Consigny
A61K 38/005A61L 27/38A61K 38/44A61K 33/00A61L 2300/40A61K 9/00A61K 31/198A61L 31/16A61P 9/10A61L 29/16
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compositions for inducing apoptosis of cells, such as macrophages, at a lesioned site of a body vessel are disclosed herein. Nitric oxide can be directly or indirectly delivered to a treatment site to increase macrophage apoptosis. Delivery can include site specific delivery of nitric oxide gas, nitric oxide in aqueous solution or a substance(s) which releases nitric oxide or causes nitric oxide to be generated from an endogenous source. Delivery can be achieved by a delivery system such as a catheter assembly, stent or other suitable device.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A composition comprising:
 an amount of an agent suitable for delivery into a body vessel wherein the agent directly or indirectly induces cell apoptosis at a lesioned site.   
     
     
         2 . The composition of  claim 1 , wherein the agent is encapsulated within a carrier. 
     
     
         3 . The composition of  claim 2 , wherein the carrier is selected from the group consisting of an implantable medical device, a microsphere, a nanoparticle, a gel, a gel depot, a hydrogel, a hydrogel depot, a polymer and a polymer depot. 
     
     
         4 . The composition of  claim 1 , wherein the agent is a nitric oxide source. 
     
     
         5 . The composition of  claim 4 , wherein the nitric oxide source is selected from the group consisting of a nitric oxide gas, a nitric oxide solution or a nitric oxide derivative solution. 
     
     
         6 . The composition of  claim 1 , wherein the agent is an amino acid. 
     
     
         7 . The composition of  claim 6 , wherein the amino acid is L-arginine or a polypeptide of L-arginine. 
     
     
         8 . The composition of  claim 1 , wherein the agent is adapted to inhibit arginase I or arginase II. 
     
     
         9 . The composition of  claim 1 , wherein the agent further comprises:
 a first agent; and   a second agent.   
     
     
         10 . The composition of  claim 9 , wherein the first agent is selected from the group consisting of a nitric oxide-containing compound and L-arginine. 
     
     
         11 . The composition of  claim 10 , wherein the second agent is selected from the group consisting of a compound suitable for reacting with the nitric oxide-containing compound and nitric oxide synthase. 
     
     
         12 . The composition of  claim 9 , wherein the first agent and the second agent are encapsulated within a carrier. 
     
     
         13 . The composition of  claim 9 , wherein the first agent or the second agent is encapsulated within a carrier. 
     
     
         14 . The composition of  claim 12 , wherein the carrier is selected from the group consisting of an implantable medical device, a microsphere, a nanoparticle, a gel, a gel depot, a hydrogel, a hydrogel depot, a polymer and a polymer depot. 
     
     
         15 . The composition of  claim 13 , wherein the carrier is selected from the group consisting of an implantable medical device, a microsphere, a nanoparticle, a gel, a gel depot, a hydrogel, a hydrogel depot, a polymer and a polymer depot. 
     
     
         16 . The composition of  claim 1 , wherein the cell is at least one macrophage cell. 
     
     
         17 . A treatment kit comprising:
 a nitric oxide source; and   a delivery device.   
     
     
         18 . The kit of  claim 17 , wherein the nitric oxide source is encapsulated in a carrier. 
     
     
         19 . The kit of  claim 17 , wherein the nitric oxide source is selected from the group consisting of a nitric oxide gas, a nitric oxide solution, a nitric oxide composition and L-arginine. 
     
     
         20 . The kit of  claim 19 , wherein the nitric oxide composition includes a first agent and a second agent. 
     
     
         21 . The kit of  claim 20 , wherein the first agent is selected from the group consisting of a nitric oxide-containing compound and L-arginine. 
     
     
         22 . The kit of  claim 20 , wherein the second agent is selected from the group consisting of a compound suitable for reacting with the nitric oxide-containing compound and nitric oxide synthase. 
     
     
         23 . The kit of  claim 20 , wherein the first agent and the second agent are encapsulated within a carrier. 
     
     
         24 . The kit of  claim 20 , wherein the first agent or the second agent is encapsulated within a carrier. 
     
     
         25 . The kit of  claim 23 , wherein the carrier is selected from the group consisting of an implantable medical device, microspheres, nanoparticles, a gel, a gel depot, a hydrogel, a hydrogel depot, a polymer and a polymer depot. 
     
     
         26 . The kit of  claim 24 , wherein the carrier is selected from the group consisting of an implantable medical device, microspheres, nanoparticles, a gel, a gel depot, a hydrogel, a hydrogel depot, a polymer and a polymer depot. 
     
     
         27 . The kit of  claim 17 , wherein the delivery device is a catheter assembly.

Join the waitlist — get patent alerts

Track US2014154300A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.